It has also been observed that the incidence of PD in patients with T2D was significantly lower in those given GLP-1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors compared with individuals prescribed any other oral combination therapy for diabetes [22–24]. Here, DPP4 is linked to Parkinson disease.